GeneVentiv Therapeutics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $2.5M

  • Investors
  • 3

GeneVentiv Therapeutics General Information

Description

Developer of preclinical adeno-associated virus gene therapies designed to treat hematologic and metabolic genetic disorders. The company develops viral vector therapies for hemophilia and Pompe disease, including gene delivery and targeted gene editing technologies, enabling researchers and healthcare providers to develop treatments for rare genetic diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 150 Fayetteville Street
  • Suite 2300
  • Raleigh, NC 27601
  • United States
+1 (919)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • 150 Fayetteville Street
  • Suite 2300
  • Raleigh, NC 27601
  • United States
+1 (919)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GeneVentiv Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Grant 16-Apr-2024 $2.5M Completed Generating Revenue
3. Seed Round 02-Aug-2022 Completed Pre-Clinical Trials
2. Accelerator/Incubator 08-Feb-2022 $50K $50K Completed Pre-Clinical Trials
1. Spin-Off 01-Jan-2020 Completed Generating Revenue
To view GeneVentiv Therapeutics’s complete valuation and funding history, request access »

GeneVentiv Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed
To view GeneVentiv Therapeutics’s complete cap table history, request access »

GeneVentiv Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GeneVentiv Therapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
National Institutes of Health Government
KickStart Venture Services Accelerator/Incubator Minority
University of North Carolina at Chapel Hill University
To view GeneVentiv Therapeutics’s complete investors history, request access »

GeneVentiv Therapeutics FAQs

  • When was GeneVentiv Therapeutics founded?

    GeneVentiv Therapeutics was founded in 2020.

  • Where is GeneVentiv Therapeutics headquartered?

    GeneVentiv Therapeutics is headquartered in Raleigh, NC.

  • What is the size of GeneVentiv Therapeutics?

    GeneVentiv Therapeutics has 4 total employees.

  • What industry is GeneVentiv Therapeutics in?

    GeneVentiv Therapeutics’s primary industry is Biotechnology.

  • Is GeneVentiv Therapeutics a private or public company?

    GeneVentiv Therapeutics is a Private company.

  • What is GeneVentiv Therapeutics’s current revenue?

    The current revenue for GeneVentiv Therapeutics is .

  • How much funding has GeneVentiv Therapeutics raised over time?

    GeneVentiv Therapeutics has raised $1.7M.

  • Who are GeneVentiv Therapeutics’s investors?

    National Institutes of Health, KickStart Venture Services, and University of North Carolina at Chapel Hill have invested in GeneVentiv Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process